309
Participants
Start Date
October 24, 2023
Primary Completion Date
December 27, 2024
Study Completion Date
June 30, 2026
TBAJ-876
tablet
Pretomanid
200 mg
Linezolid
600 mg
Bedaquiline
200 mg for 8 weeks followed by 100 mg for 18 weeks
HRZE
Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
HR
Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
Lung Center of the Philippines, Quezon City
Tropical Disease Foundation, Makati City
WITS, Clinical HIV Research Unit (CHRU) Themba Lethu Clinic, Helen Joseph Hospital, Johannesburg
Perinatal HIV Research Unit (PHRU), Klerksdorp
The Aurum Institute, Rustenburg
TB and HIV Investigative Network (THINK), Hillcrest
Enhancing Care Foundation, Durban
Care Clinical Trial Group Inc., Dasmariñas
Synergy Biomed Research Institute (SBRI), East London
Isango Lethemba TB Research Unit, Port Elizabeth
TASK Eden, George
TASK Brooklyn, Cape Town
University of Cape Town Lung Institute (UCTLI), Cape Town
Desmond Tutu Health Foundation, Cape Town
National Center for Tuberculosis and Lung Diseases, Tbilisi
Setshaba Research Centre, Soshanguve
Madibeng Centre for Research, Brits
NIMR-MBEYA Medical Research Center, Mbeya
Kilimanjaro Christian Medical Centre, Moshi
National Institute for Medical Research (NIMR), Mwanza
Case Western Reserve University- Research collaboration Uganda, Kampala
Joint Clinical Research Centre (JCRC), Kampala
Global Alliance for TB Drug Development
OTHER